Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies

免疫原 中和 单克隆抗体 表位 抗体 病毒学 免疫系统 化学 生物 免疫学
作者
Qingwen He,Yaling An,Xuemei Zhou,Haitang Xie,Lifeng Tao,Dedong Li,Anqi Zheng,Linjie Li,Zepeng Xu,Shufan Yu,Ruyue Wang,Hua Hu,Kefang Liu,Qihui Wang,Lianpan Dai,Kun Xu,George F. Gao
出处
期刊:Med [Elsevier BV]
卷期号:5 (5): 401-413.e4 被引量:13
标识
DOI:10.1016/j.medj.2024.03.006
摘要

Background The recently circulating Omicron variants BA.2.86 and JN.1 were identified with more than 30 amino acid changes on the spike protein compared to BA.2 or XBB.1.5. This study aimed to comprehensively assess the immune escape potential of BA.2.86, JN.1, EG.5, and EG.5.1. Methods We collected human and murine sera to evaluate serological neutralization activities. The participants received three doses of coronavirus disease 2019 (COVID-19) vaccines or a booster dose of the ZF2022-A vaccine (Delta-BA.5 receptor-binding domain [RBD]-heterodimer immunogen) or experienced a breakthrough infection (BTI). The ZF2202-A vaccine is under clinical trial study (ClinicalTrials.gov: NCT05850507). BALB/c mice were vaccinated with a panel of severe acute respiratory syndrome coronavirus 2 RBD-dimer proteins. The antibody evasion properties of these variants were analyzed with 41 representative human monoclonal antibodies targeting the eight RBD epitopes. Findings We found that BA.2.86 had less neutralization evasion than EG.5 and EG.5.1 in humans. The ZF2202-A booster induced significantly higher neutralizing titers than BTI. Furthermore, BA.2.86 and JN.1 exhibited stronger antibody evasion than EG.5 and EG.5.1 on RBD-4 and RBD-5 epitopes. Compared to BA.2.86, JN.1 further lost the ability to bind to several RBD-1 monoclonal antibodies and displayed further immune escape. Conclusions Our data showed that the currently dominating sub-variant, JN.1, showed increased immune evasion compared to BA.2.86 and EG.5.1, which is highly concerning. This study provides a timely risk assessment of the interested sub-variants and the basis for updating COVID-19 vaccines. Funding This work was funded by the National Key R&D Program of China, the National Natural Science Foundation of China, the Beijing Life Science Academy, the Bill & Melinda Gates Foundation, and the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation (CPSF).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
壹贰完成签到 ,获得积分10
1秒前
yinshan完成签到 ,获得积分10
2秒前
vera完成签到,获得积分10
9秒前
kangkang完成签到 ,获得积分10
10秒前
Chen完成签到 ,获得积分10
11秒前
cuddly完成签到 ,获得积分10
11秒前
12秒前
gyf完成签到,获得积分10
12秒前
邢哥哥完成签到,获得积分20
13秒前
Agamemnon完成签到,获得积分10
15秒前
不如看海完成签到 ,获得积分10
17秒前
村长热爱美丽完成签到 ,获得积分10
18秒前
南梦娇完成签到 ,获得积分10
20秒前
科研小郭完成签到,获得积分10
20秒前
科研人完成签到,获得积分10
21秒前
22秒前
25秒前
30秒前
Wang发布了新的文献求助10
32秒前
沉默乐安完成签到,获得积分10
32秒前
瘦瘦的迎南完成签到 ,获得积分10
34秒前
storm完成签到,获得积分10
35秒前
微笑代荷完成签到 ,获得积分10
36秒前
玩命的糖豆完成签到 ,获得积分10
37秒前
行云流水完成签到 ,获得积分10
37秒前
38秒前
科研通AI2S应助科研通管家采纳,获得50
38秒前
鲤鱼完成签到,获得积分10
39秒前
香翔想相完成签到,获得积分10
46秒前
gy完成签到 ,获得积分20
47秒前
葡紫明完成签到 ,获得积分10
49秒前
科研通AI5应助轻蹈云巅采纳,获得10
50秒前
violetlishu完成签到 ,获得积分10
52秒前
典雅雅容完成签到,获得积分10
53秒前
bclddmy完成签到,获得积分10
54秒前
qiao完成签到,获得积分10
54秒前
xinjiasuki完成签到 ,获得积分10
58秒前
榕俊完成签到,获得积分10
1分钟前
LLL完成签到,获得积分10
1分钟前
初见关注了科研通微信公众号
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
高温高圧下融剤法によるダイヤモンド単結晶の育成と不純物の評価 5000
Aircraft Engine Design, Third Edition 500
Neonatal and Pediatric ECMO Simulation Scenarios 500
苏州地下水中新污染物及其转化产物的非靶向筛查 500
Rapid Review of Electrodiagnostic and Neuromuscular Medicine: A Must-Have Reference for Neurologists and Physiatrists 500
Vertebrate Palaeontology, 5th Edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4742598
求助须知:如何正确求助?哪些是违规求助? 4092256
关于积分的说明 12657568
捐赠科研通 3803370
什么是DOI,文献DOI怎么找? 2099751
邀请新用户注册赠送积分活动 1125193
关于科研通互助平台的介绍 1001452